Cyclacel Pharmaceuticals Declares Quarterly Cash Dividend

The latest update is out from Cyclacel Pharmaceuticals ( (CYCC) ).

On June 3, 2025, Cyclacel Pharmaceuticals‘ Board of Directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock, payable on August 1, 2025, to stockholders of record as of July 21, 2025. This announcement reflects the company’s commitment to providing returns to its investors and may influence its market positioning by demonstrating financial stability and shareholder value.

The most recent analyst rating on (CYCC) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Cyclacel Pharmaceuticals stock, see the CYCC Stock Forecast page.

Spark’s Take on CYCC Stock

According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.

Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.

To see Spark’s full report on CYCC stock, click here.

More about Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapies for cancer and other serious diseases.

Average Trading Volume: 199,251

Technical Sentiment Signal: Strong Sell

Current Market Cap: $36.53M

Learn more about CYCC stock on TipRanks’ Stock Analysis page.